




Clearsight Advisors[®]
Investment Banking



Q3 2026

Healthcare and Life Sciences Services Market Monitor

Market Update, Industry News, Sector Spotlight, and M&A Activity



Select Industry News

Acumetis Selects Ramil Burden to Lead Next Phase of Growth

Bringing experience across commercialization, market access, payer strategy, analytics, and life sciences services, Burden joins Acumetis as CEO to lead its next chapter of growth. The appointment reflects the firm's continued focus on helping life sciences organizations navigate increasingly complex commercialization challenges. ([Link](#))¹

Chris Librizzi Joins Marwood Group as CEO

Librizzi joins Marwood from EY-Parthenon, where he led the firm's U.S. strategy consulting business and helped drive growth across new client segments and service offerings. He will lead Marwood as the healthcare advisory firm expands its capabilities across strategy, compliance, performance improvement, and healthcare market intelligence. ([Link](#))²

Clinigen Appoints Greg Skalicky as CEO

Skalicky joins Clinigen with more than 30 years of clinical and commercial expertise in the pharmaceutical, biotechnology, and healthcare sectors, most recently serving as President of Eversana. He will lead Clinigen's next growth phase as it expands its pharmaceutical services platform and patient access capabilities. ([Link](#))³

Inizio Expands Global Medical Information Capabilities

Inizio introduced Connected Insights through Inizio Engage, combining expanded APAC expertise, enhanced global infrastructure, and AI-enabled tools to help life sciences organizations generate intelligence and deliver consistent medical information. The capabilities are designed to advance Inizio's Medical Affairs strategy, improve engagement, and drive value across the product lifecycle. ([Link](#))⁴

IQVIA Launches AI-Powered Clinical Development Platform

IQVIA introduced Predictive Clinical Development, a new AI-powered approach designed to help life sciences companies reduce clinical trial delays and accelerate the path from development to commercialization. The offering combines proprietary data, regulatory expertise, and advanced AI capabilities to make development faster, higher quality, and more predictable. ([Link](#))⁵

Lundbeck and EVERSANA Partner to Advance AI-Powered Commercialization

Lundbeck and EVERSANA expanded their partnership to advance AI-powered capabilities across strategy development, content creation, and customer engagement. Building on earlier initiatives, the partnership aims to further support life sciences organizations in improving execution while maintaining the compliance and scientific standards required across the industry. ([Link](#))⁶

PhRMA Selects Eric Cantor as President and CEO

Drawing on experience across public policy and business leadership, Cantor will lead PhRMA as it works to advance policies that support biopharmaceutical innovation and patient access to medicines. The appointment comes at a pivotal time for the industry as companies continue to invest in new therapies and emerging technologies. ([Link](#))⁷

Sector Leadership



Greg Tregger
Managing Director
[Email Greg](#)



Tory Steel
Managing Director
[Email Tory](#)



Austin Kuhn
Director
[Email Austin](#)



Jonathan Holland
Vice President
[Email Jonathan](#)

Target**van den Boom & Associates**Acquirer**Gridiron Capital****Deal Commentary**

- van den Boom & Associates ("vdB&A") provides embedded finance, accounting, HR, compliance, contract management, and IT support services to the biotech industry
- Gridiron's investment supports vdB&A's continued growth through investments in talent, technology, data-driven capabilities, and expanded service offerings

Transaction Summary

On August 12, 2026, Gridiron Capital announced a strategic investment in van den Boom & Associates. The transaction supports the Company's continued growth and enhances its ability to help life sciences organizations manage critical operational functions as they scale from emerging ventures to public companies

Clearsight advised vdB&A on this transaction.

Transaction Information

Announced Date	August 12, 2026
Deal Type	Majority Recapitalization
<i>Target Information</i>	
Year Founded	2014
Target HQ	San Diego, CA
# of Employees	~130

Target**Ambit**Acquirer**Danforth Health***(Avesi Partners)***Deal Commentary**

- Ambit combines proprietary data, advanced analytics, and deep domain expertise to deliver integrated solutions that address critical commercial needs across the rare and specialty disease markets
- The acquisition enhances Danforth's broader solution offering and creates meaningful opportunities to cross-sell complementary capabilities across both companies' existing customer relationships


Transaction Summary

On September 9, 2026, Danforth Health announced its acquisition of Ambit. The acquisition strengthens the capability set of the combined organization, uniting commercial strategy, data, and technology expertise with end-to-end business and clinical capabilities to better support clients throughout the product journey

Clearsight advised Ambit on this transaction.

Transaction Information

Announced Date	September 9, 2026
Deal Type	Acquisition
<i>Target Information</i>	
Year Founded	2021
Target HQ	Morristown, NJ
# of Employees	~100

Healthcare and Life Sciences Services Deal Volume¹

1. Time series data based on Clearsight's custom PitchBook screen intended to show trends over time and should be interpreted as directional regarding deal volume. Please email the Clearsight team for specific screen-related questions.



Announced Date	Target	Buyer	Summary
9/29/26	Marwood Group	Lee Equity Partners	Marwood Group is a healthcare-focused consulting firm providing policy, regulatory, reimbursement, and performance improvement services for healthcare, life sciences, and private equity clients
9/28/26	Evolution Consulting & Research	TJP (Renovus Capital)	Evolution Consulting & Research is a life sciences market research and commercial strategy consultancy that provides qualitative and quantitative research, competitive analysis, and commercialization support
9/14/26	Bluefin	Endpoint Clinical (Arsenal Capital Partners)	Bluefin is a provider of clinical supply forecasting and planning software that helps pharmaceutical companies optimize clinical trial supply chains
9/10/26	Relevate Health Group (Mountaingate Capital)	Linden Capital	Relevate Health is an omnichannel marketing solutions firm that helps pharmaceutical, biotechnology, and healthcare organizations drive healthcare provider engagement and improve clinical decision-making
9/9/26	Ambit	Danforth Health (Avesi Partners)	Ambit is a technology-enabled consultancy specializing in commercial strategy, advanced analytics, and patient identification for rare and specialty biopharma companies
9/9/26	Accumulus Technologies	Eir Partners	Accumulus Technologies is a cloud-based regulatory collaboration platform that connects life sciences companies with global health authorities, enabling real-time data exchange to accelerate drug development and regulatory approvals
9/7/26	Dark Peak Analytics	Initiate (Queen's Park Equity)	Dark Peak Analytics is a health economics and analytics consultancy specializing in health economic modeling, model modernization, and technology-enabled solutions for life sciences companies
9/2/26	Outcomes One (BlackRock)	H.I.G. Capital	Outcomes One is a healthcare technology company specializing in clinical network services and pharmacy technology solutions for pharmacies, health plans, pharmaceutical manufacturers, and data partners

Source: Pitchbook, company websites, Business Wire, Public filings.



Announced Date	Target	Buyer	Summary
8/26/26	Pixel Health	Thurston Group	Pixel Health is a healthcare IT consulting and managed services provider that helps hospitals and physician groups implement and optimize technology solutions
8/25/26	Precision Medicine Group (Blackstone)	McKesson	Precision Medicine Group is a life sciences services platform that provides clinical development, commercialization, and consulting services to biopharmaceutical and biotechnology companies across the product lifecycle
8/18/26	Humata Health	R1 RCM (TowerBrook, CD&R)	Humata Health is an AI-powered prior authorization technology company that streamlines payer-provider collaboration and automates medical authorization workflows for healthcare organizations
8/12/26	van den Boom & Associates	Gridiron Capital	van den Boom & Associates is a provider of operational support services spanning finance, accounting, human resources, compliance, contract management, and managed IT for life sciences companies
7/8/26	Quante Intelligence¹	Graham Partners	Quante Intelligence is a decision sciences platform providing biometrics services to transform complex clinical data into confident, regulatory-ready decisions for life sciences clients
7/6/26	Clarivate Life Sciences and Healthcare Division	Altaris	The Clarivate Life Sciences and Healthcare division offers data, intelligence, and consulting solutions to pharmaceutical, biotechnology, and medical device companies across the product lifecycle
7/2/26	Asembia	Peak Rock Capital	Asembia is a provider of technology-enabled commercialization, patient support, and group purchasing solutions for the specialty pharmacy industry
7/1/26	Momentum Life Sciences	Parthenon Capital	Momentum Life Sciences is a patient engagement, adherence, and clinical nurse education solutions company that helps patients start and remain on specialty therapies

1. New Platform formed by acquiring TechData, LLX, and R Square.

Source: Pitchbook, company websites, Business Wire, Public filings.



About Clearsight

Clearsight's Healthcare and Life Sciences Practice focuses on 'Knowledge Economy' businesses serving life sciences companies, providers, and payers. This ecosystem is innovating across professional services, technology, and data to move healthcare forward.

Clearsight Advisors is an investment banking firm dedicated to driving the Knowledge Economy by providing world-class M&A and capital raising solutions exclusively to growth-oriented Business Services and Technology companies. Clearsight combines deep market insights across software, services, and data. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. All securities are offered exclusively through RF M&A Securities LLC, a registered broker-dealer and member of [FINRA](#) and [SIPC](#). For more information about Clearsight, visit www.clearsightadvisors.com.

 1650 Tysons Boulevard
Suite 710
McLean, VA 22102

250 Park Avenue
Suite 600
New York, NY 10177

 703.672.3100

 www.clearsightadvisors.com

 [Clearsight Advisors](#)

Select Transactions



This publication has been prepared solely for the use of institutional investors for general information purposes and is not to be construed as: a personalized recommendation; a solicitation or an offer to buy or sell any securities or related financial instruments; legal, tax, financial or accounting advice. Contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Clearsight has no duty to update the information. Certain sections of this publication may contain forward-looking statements that are based on the reasonable expectations, estimates, projections and assumptions of the authors, but forward-looking statements are not guarantees of future performance and involve risks and uncertainties, which are difficult to predict. The names and marks of other companies or their services or products may be the trademarks of their owners and are used only to identify such companies or their services or products and not to indicate endorsement or sponsorship of Clearsight of its services or products. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. All securities are offered through RF M&A Services LLC, a registered broker-dealer and member of [FINRA](#) and [SIPC](#). For more information about Clearsight visit www.clearsightadvisors.com.